Cargando…
The Kaiser score reliably excludes malignancy in benign contrast-enhancing lesions classified as BI-RADS 4 on breast MRI high-risk screening exams
OBJECTIVES: MRI is an integral part of breast cancer screening in high-risk patients. We investigated whether the application of the Kaiser score, a clinical decision-support tool, may be used to exclude malignancy in contrast-enhancing lesions classified as BI-RADS 4 on breast MRI screening exams....
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553895/ https://www.ncbi.nlm.nih.gov/pubmed/32504098 http://dx.doi.org/10.1007/s00330-020-06945-z |
_version_ | 1783593697678458880 |
---|---|
author | Milos, Ruxandra Iulia Pipan, Francesca Kalovidouri, Anastasia Clauser, Paola Kapetas, Panagiotis Bernathova, Maria Helbich, Thomas H. Baltzer, Pascal A. T. |
author_facet | Milos, Ruxandra Iulia Pipan, Francesca Kalovidouri, Anastasia Clauser, Paola Kapetas, Panagiotis Bernathova, Maria Helbich, Thomas H. Baltzer, Pascal A. T. |
author_sort | Milos, Ruxandra Iulia |
collection | PubMed |
description | OBJECTIVES: MRI is an integral part of breast cancer screening in high-risk patients. We investigated whether the application of the Kaiser score, a clinical decision-support tool, may be used to exclude malignancy in contrast-enhancing lesions classified as BI-RADS 4 on breast MRI screening exams. METHODS: This retrospective study included 183 consecutive, histologically proven, suspicious (MR BI-RADS 4) lesions detected within our local high-risk screening program. All lesions were evaluated according to the Kaiser score for breast MRI by three readers blinded to the final histopathological diagnosis. The Kaiser score ranges from 1 (lowest, cancer very unlikely) to 11 (highest, cancer very likely) and reflects increasing probabilities of malignancy, with scores greater than 4 requiring biopsy. Receiver operating characteristic (ROC) curve analysis was used to evaluate diagnostic accuracy. RESULTS: There were 142 benign and 41 malignant lesions, diagnosed in 159 patients (mean age, 43.6 years). Median Kaiser scores ranged between 2 and 5 in benign and 7 and 8 in malignant lesions. For all lesions, the Kaiser score’s accuracy, represented by the area under the curve (AUC), ranged between 86.5 and 90.2. The sensitivity of the Kaiser score was high, between 95.1 and 97.6% for all lesions, and was best in mass lesions. Application of the Kaiser score threshold for malignancy (≤ 4) could have potentially avoided 64 (45.1%) to 103 (72.5%) unnecessary biopsies in 142 benign lesions previously classified as BI-RADS 4. CONCLUSIONS: The use of Kaiser score in high-risk MRI screening reliably excludes malignancy in more than 45% of contrast-enhancing lesions classified as BI-RADS 4. KEY POINTS: • The Kaiser score shows high diagnostic accuracy in identifying malignancy in contrast-enhancing lesions in patients undergoing high-risk screening for breast cancer. • The application of the Kaiser score may avoid > 45% of unnecessary breast biopsies in high-risk patients. • The Kaiser score aids decision-making in high-risk breast cancer MRI screening programs. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00330-020-06945-z) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-7553895 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-75538952020-10-19 The Kaiser score reliably excludes malignancy in benign contrast-enhancing lesions classified as BI-RADS 4 on breast MRI high-risk screening exams Milos, Ruxandra Iulia Pipan, Francesca Kalovidouri, Anastasia Clauser, Paola Kapetas, Panagiotis Bernathova, Maria Helbich, Thomas H. Baltzer, Pascal A. T. Eur Radiol Breast OBJECTIVES: MRI is an integral part of breast cancer screening in high-risk patients. We investigated whether the application of the Kaiser score, a clinical decision-support tool, may be used to exclude malignancy in contrast-enhancing lesions classified as BI-RADS 4 on breast MRI screening exams. METHODS: This retrospective study included 183 consecutive, histologically proven, suspicious (MR BI-RADS 4) lesions detected within our local high-risk screening program. All lesions were evaluated according to the Kaiser score for breast MRI by three readers blinded to the final histopathological diagnosis. The Kaiser score ranges from 1 (lowest, cancer very unlikely) to 11 (highest, cancer very likely) and reflects increasing probabilities of malignancy, with scores greater than 4 requiring biopsy. Receiver operating characteristic (ROC) curve analysis was used to evaluate diagnostic accuracy. RESULTS: There were 142 benign and 41 malignant lesions, diagnosed in 159 patients (mean age, 43.6 years). Median Kaiser scores ranged between 2 and 5 in benign and 7 and 8 in malignant lesions. For all lesions, the Kaiser score’s accuracy, represented by the area under the curve (AUC), ranged between 86.5 and 90.2. The sensitivity of the Kaiser score was high, between 95.1 and 97.6% for all lesions, and was best in mass lesions. Application of the Kaiser score threshold for malignancy (≤ 4) could have potentially avoided 64 (45.1%) to 103 (72.5%) unnecessary biopsies in 142 benign lesions previously classified as BI-RADS 4. CONCLUSIONS: The use of Kaiser score in high-risk MRI screening reliably excludes malignancy in more than 45% of contrast-enhancing lesions classified as BI-RADS 4. KEY POINTS: • The Kaiser score shows high diagnostic accuracy in identifying malignancy in contrast-enhancing lesions in patients undergoing high-risk screening for breast cancer. • The application of the Kaiser score may avoid > 45% of unnecessary breast biopsies in high-risk patients. • The Kaiser score aids decision-making in high-risk breast cancer MRI screening programs. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00330-020-06945-z) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2020-06-06 2020 /pmc/articles/PMC7553895/ /pubmed/32504098 http://dx.doi.org/10.1007/s00330-020-06945-z Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Breast Milos, Ruxandra Iulia Pipan, Francesca Kalovidouri, Anastasia Clauser, Paola Kapetas, Panagiotis Bernathova, Maria Helbich, Thomas H. Baltzer, Pascal A. T. The Kaiser score reliably excludes malignancy in benign contrast-enhancing lesions classified as BI-RADS 4 on breast MRI high-risk screening exams |
title | The Kaiser score reliably excludes malignancy in benign contrast-enhancing lesions classified as BI-RADS 4 on breast MRI high-risk screening exams |
title_full | The Kaiser score reliably excludes malignancy in benign contrast-enhancing lesions classified as BI-RADS 4 on breast MRI high-risk screening exams |
title_fullStr | The Kaiser score reliably excludes malignancy in benign contrast-enhancing lesions classified as BI-RADS 4 on breast MRI high-risk screening exams |
title_full_unstemmed | The Kaiser score reliably excludes malignancy in benign contrast-enhancing lesions classified as BI-RADS 4 on breast MRI high-risk screening exams |
title_short | The Kaiser score reliably excludes malignancy in benign contrast-enhancing lesions classified as BI-RADS 4 on breast MRI high-risk screening exams |
title_sort | kaiser score reliably excludes malignancy in benign contrast-enhancing lesions classified as bi-rads 4 on breast mri high-risk screening exams |
topic | Breast |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553895/ https://www.ncbi.nlm.nih.gov/pubmed/32504098 http://dx.doi.org/10.1007/s00330-020-06945-z |
work_keys_str_mv | AT milosruxandraiulia thekaiserscorereliablyexcludesmalignancyinbenigncontrastenhancinglesionsclassifiedasbirads4onbreastmrihighriskscreeningexams AT pipanfrancesca thekaiserscorereliablyexcludesmalignancyinbenigncontrastenhancinglesionsclassifiedasbirads4onbreastmrihighriskscreeningexams AT kalovidourianastasia thekaiserscorereliablyexcludesmalignancyinbenigncontrastenhancinglesionsclassifiedasbirads4onbreastmrihighriskscreeningexams AT clauserpaola thekaiserscorereliablyexcludesmalignancyinbenigncontrastenhancinglesionsclassifiedasbirads4onbreastmrihighriskscreeningexams AT kapetaspanagiotis thekaiserscorereliablyexcludesmalignancyinbenigncontrastenhancinglesionsclassifiedasbirads4onbreastmrihighriskscreeningexams AT bernathovamaria thekaiserscorereliablyexcludesmalignancyinbenigncontrastenhancinglesionsclassifiedasbirads4onbreastmrihighriskscreeningexams AT helbichthomash thekaiserscorereliablyexcludesmalignancyinbenigncontrastenhancinglesionsclassifiedasbirads4onbreastmrihighriskscreeningexams AT baltzerpascalat thekaiserscorereliablyexcludesmalignancyinbenigncontrastenhancinglesionsclassifiedasbirads4onbreastmrihighriskscreeningexams AT milosruxandraiulia kaiserscorereliablyexcludesmalignancyinbenigncontrastenhancinglesionsclassifiedasbirads4onbreastmrihighriskscreeningexams AT pipanfrancesca kaiserscorereliablyexcludesmalignancyinbenigncontrastenhancinglesionsclassifiedasbirads4onbreastmrihighriskscreeningexams AT kalovidourianastasia kaiserscorereliablyexcludesmalignancyinbenigncontrastenhancinglesionsclassifiedasbirads4onbreastmrihighriskscreeningexams AT clauserpaola kaiserscorereliablyexcludesmalignancyinbenigncontrastenhancinglesionsclassifiedasbirads4onbreastmrihighriskscreeningexams AT kapetaspanagiotis kaiserscorereliablyexcludesmalignancyinbenigncontrastenhancinglesionsclassifiedasbirads4onbreastmrihighriskscreeningexams AT bernathovamaria kaiserscorereliablyexcludesmalignancyinbenigncontrastenhancinglesionsclassifiedasbirads4onbreastmrihighriskscreeningexams AT helbichthomash kaiserscorereliablyexcludesmalignancyinbenigncontrastenhancinglesionsclassifiedasbirads4onbreastmrihighriskscreeningexams AT baltzerpascalat kaiserscorereliablyexcludesmalignancyinbenigncontrastenhancinglesionsclassifiedasbirads4onbreastmrihighriskscreeningexams |